← Back to Stock Screener← Stock Screener

ZYBERNO

Stock Report

Updated Sep 1, 2026

ELUTIA INC. (ELUT)

Healthcare • NASDAQ

$0.86

Professional Investment Analysis

ZYBERNO SCORE →

Is it a great business? Is it getting better?

32.0/100

WEAK BUSINESS

ELUTIA INC. (ELUT) scores 32/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.

📊 How is the Zyberno Score calculated? +

The Zyberno Score answers one question: "Is this a quality business worth owning?" It's a 0-100 investment grade that evaluates business fundamentals across four critical dimensions, based on principles from Warren Buffett, Benjamin Graham, Peter Lynch, and Charlie Munger.

The 4 Core Categories (25 points each):

1. PROFITABILITY (25 pts)

Metrics: ROE, ROIC, Net Margin, Operating Margin
Thresholds: ROE >20% excellent • ROIC >20% excellent • Net Margin >20% excellent • Operating Margin >25% excellent

2. FINANCIAL STRENGTH (25 pts)

Metrics: Debt-to-Equity, Current Ratio, Interest Coverage, Altman Z-Score
Thresholds: D/E <0.3 excellent • Current Ratio >2.5 excellent • Interest Coverage >10x excellent • Altman Z >3.0 safe

3. CASH FLOW QUALITY (25 pts)

Metrics: Free Cash Flow, OCF vs Net Income, FCF Margin
Thresholds: Positive & growing FCF excellent • OCF/NI >1.2x excellent (cash earnings exceed accounting)

4. GROWTH & CONSISTENCY (25 pts)

Metrics: Revenue Growth, Net Income Growth, FCF Growth, Piotroski F-Score
Thresholds: Growth via log-linear regression • Piotroski 8-9 excellent, 6-7 good

Score Interpretation:

75-100

GREAT BUSINESS

65-74

GOOD BUSINESS

50-64

AVERAGE BUSINESS

30-49

WEAK BUSINESS

0-29

POOR BUSINESS

→ View full ELUT quality analysis & detailed breakdown

VALUATION SIGNAL

N/A (Requires more data)

Requires fair value calculation and current price data

💰 How is Margin of Safety calculated? +

Margin of Safety measures how much discount or premium you're paying relative to a stock's intrinsic value. It's Benjamin Graham's core principle: the larger the margin, the lower your downside risk.

Formula: (Intrinsic Value − Current Price) ÷ Intrinsic Value × 100%

How We Calculate Intrinsic Value (DCF Method):

Step 1: Calculate current Owner Earnings (OCF − Maintenance CapEx)

Step 2: Calculate company-specific growth rate using log-linear regression on 16 quarters of Owner Earnings

Step 3: Project 10 years forward using the calculated growth rate

Step 4: Discount each year's cash flow to present value using 10% discount rate

Step 5: Calculate terminal value using 3% perpetual growth rate

Step 6: Sum all discounted cash flows = Intrinsic Value

What The Percentages Mean:

+50% or more

EXCELLENT — Very undervalued

+25% to +50%

GOOD — Attractive discount

0% to +25%

FAIR — Reasonable value

0% to -25%

CAUTION — Slight premium

-25% or worse

POOR — Overvalued

"Price is what you pay, value is what you get." — Warren Buffett

→ View full ELUT valuation analysis · → View full ELUT Brina Gap analysis

📈 How is Brina Gap calculated? +

Brina Gap measures the difference between the growth a business can fundamentally sustain and the growth the market is already pricing in.

Formula: Fundamental Growth Rate − Market-Implied Growth Rate

The Two Components:

Fundamental Growth Rate = ROIC × Reinvestment Rate

What the business can sustainably grow at based on how much it reinvests and what return it earns on that capital. Grounded in historical financials.

Market-Implied Growth Rate = Reverse DCF

The growth rate the current Enterprise Value implicitly assumes. Calculated by back-solving a 10-year DCF model (10% WACC, 3% terminal growth) until the present value of projected cash flows equals EV.

What The Gap Means:

Gap > +5% Market Underestimates — potential upside

+2% to +5% Slight Underestimate

-2% to +2% Fairly Priced — market consensus matches fundamentals

-5% to -2% Slight Overestimate

Gap < -5% Market Overestimates — price embeds optimism fundamentals don't support

A positive gap (market underestimates) combined with a positive Margin of Safety is the strongest combined signal — the business is both cheap historically and forward economics are stronger than the price suggests.

Critical Financial Health Indicators

Return on Equity (Profitability):NEUTRAL (940.8%)

Debt-to-Equity (Solvency Risk):GOOD (0.49x)

Operating Margin (Operational Efficiency):CRITICAL (-131.3%)

Return on Capital (Capital Efficiency):CRITICAL (-7,636.6%)

📊 Valuation Trilogy

Three interconnected metrics for complete valuation analysis

Click any metric for full methodology and detailed analysis

Zyberno's Verdict

ELUTIA INC. (ELUT) stock report — Zyberno Score 32/100 (WEAK BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, ELUT generated -$45.13M in Owner Earnings. Capital was deployed as follows: $2.06M invested in capital expenditures. Reinvestment rate: 463.1%.

DIVISION I: EXECUTIVE SUMMARY

A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.86

Market Cap:$38.21M

Valuation Multiples (4)

P/E Ratio:

0.86x

📊 Click to view full ELUT P/E analysis →

P/B Ratio:2.43x

P/S Ratio:2.14x

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$22.70M

Price Action & Momentum (1)

% of 52-Week High:36.3%

B. Profitability Assessment

Return Metrics (5)

ROE:

940.8%

📊 Click to view full ELUT ROE analysis →

ROA:108.7%

Roic:

-7,636.6%

📊 Click to view full ELUT ROIC analysis →

Reinvestment Rate:463.1%

Fundamental Growth Rate (g):-35,367.0%

Margin Analysis (3)

Operating Margin Ttm:-131.3%

Net Margin Ttm:290.5%

Ebitda Margin:-97.4%

TTM Performance (3)

Gross Margin Ttm:55.2%

Operating Margin Ttm:-131.3%

Net Margin Ttm:290.5%

Yield Metrics (2)

Earnings Yield:$116.08

Dividend Yield:0.0%

C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

Earnings Surprise (SUE):

-0.28

📊 Click to view full ELUT Earnings Surprise analysis →

EPS Surprise vs Expected:-117.8%

Latest Earnings Filed:2026-08-14

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-28.2%

D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.77x

Quick Ratio:1.64x

Cash Ratio:0.95x

Leverage Analysis (3)

Debt To Equity Ttm:0.49x

Debt-to-Equity Ratio:0.49x

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-8.98x

Times Interest Earned:-8.98

Capital Structure (4)

Working Capital:16,170,000.00

Cash And Cash Equivalents:19,896,000.00

Long Term Debt:$3.70M

Net Debt:-$15.52M

DIVISION II: FINANCIAL STATEMENTS ANALYSIS

A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $17.83M

Linear Growth: -28.2%

📊 Click to view full ELUT Revenue analysis & methodology →

Cost Of Revenue Ttm:$7.99M

Profitability Breakdown (2)

Gross profit TTM: $9.85M

Linear Growth: -16.1%

📊 Click to view full ELUT Gross Profit analysis & methodology →

-$23.42M

Bottom Line Performance (3)

$51.81M

Income Before Tax:-$17.79M

Ebitda Ttm:-17,374,000.00

Operating Expenses (5)

Operating Expenses:27,749,000.00

R And D Expense:6,302,000.00

Sga Expense:15,059,000.00

Income Tax Expense:$91.00K

Interest Expense:2,997,000.00

Expense Ratios (3)

R And D To Revenue Percentage:259.7%

Sga To Revenue Percentage:620.5%

Ebitda Margin:-97.4%

B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$43.65M

Current Assets:$37.22M

Ppe Net:2,922,000.00

Goodwill:0.00

Intangible Assets:$990.00K

Liability Structure (4)

Total Liabilities:27,903,000.00

Current Liabilities:21,045,000.00

Long Term Debt:$3.70M

Short Term Debt:$685.00K

Equity & Capital (3)

Equity:$15.75M

Retained Earnings:-$191.33M

Common Stock:4,801,180.00

Working Capital Items (3)

Accounts Receivable:1,438,000.00

Inventory:2,649,000.00

Accounts Payable:3,531,000.00

Special Items (2)

Contract Liabilities:0.00

Stock Based Compensation:905,000.00

C. Cash Flow Analysis

Operating Activities (2)

-$43.76M-$45.82M

Investment Activities (2)

Investing Cash Flow:-$34.00K

Capital Expenditures Ttm:2,057,000.00

Financing Activities (3)

Financing Cash Flow:$3.00K

Dividends Paid Ttm:0.00

Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:13,796,000.00

Long Term Debt Issuance:$0.00

Long Term Debt Repayments:$2.00M

Non-Cash Items (1)

Depreciation Amortization Ttm:6,045,000.00

DIVISION III: OPERATIONAL METRICS

A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):1.28

$1.00

Earnings Per Share Ttm:$1.17

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.40

Operating Cash Flow Per Share:-$1.01

Book Value & Capital (2)

Book Value Per Share:$0.36

Cash Per Share:0.45

Dividend Policy (1)

Dividend Payout Ratio:0.00x

B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.37x

Working Capital Turnover Ttm:1.10x

Receivables Management (2)

Receivables Turnover Ttm:12.40x

Days Sales Outstanding Ttm:29.43

Inventory Management (2)

Inventory Turnover Ttm:3.02x

Days Inventory Outstanding Ttm:121.03

Payables & Cash Cycle (2)

Days Payable Outstanding:161.32

Cash Conversion Cycle:-10.87

C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00

Quality Score:70.00

Market Metrics (2)

Beta:0.00x

Volatility Category:unknown

DIVISION IV: INVESTMENT ANALYSIS

A. Value Investment Framework

Owner Earnings Analysis (1)

-$45.13M

Damodaran Growth Analysis (2)

Reinvestment Rate:463.1%

Fundamental Growth Rate (g):-35,367.0%

B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-28.2%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):-16.1%

Book Value Growth Rate (Linear):19.1%

C. Company Profile & Context

Corporate Information (6)

Symbol:ELUT

Company Name:ELUTIA INC.

Sector:Healthcare

Industry:Biological Products, (No Diagnostic Substances)

Exchange:NASDAQ

Country:United States

Market Classification (3)

Market Cap Category:N/A

Price Category:penny

Volume Category:N/A

Share Structure (3)

Shares Outstanding:44.22M

Shares Outstanding Basic:44.22M

Shares Outstanding Diluted:44.22M

Data Processing Info (3)

Processing Version:v3.0

Last Updated:2026-09-01 04:24:53 UTC

Data Timestamp:2026-08-20T13:22:57.702428